Figure 7
The aqueous extract from Immuplex ® and Congaplex ® reduce cytokine release by human PBMCs in a dose-dependent manner. PBMCs from 10 healthy volunteers were pre-treated with the aqueous extract from Immuplex® or Congaplex® at 0.5 mg/mL for one hour prior to treatment with PHA as described in Materials and Methods. Cells were harvested 3 days after treatment and media was assayed for cytokine concentrations using a multiplex bead assay. A) A scatter plot shows the concentration of each cytokine in the media from each of the 10 donors after treatment with PHA, in the absence of Congaplex® or Immuplex®. The average of all 10 donors is indicated as a horizontal bar ± standard deviation. For each donor, data represents the average of three replicates ± standard deviation. B) The effects of Congaplex® and Immuplex® on cytokine concentrations in the media of cells treated with PHA. Data are expressed as the percentage difference from treatment with PHA and vehicle treatment. The data are presented as the average response of the PBMCs from the 10 donors ± standard deviation. * = significantly different from the vehicle treatment.